A phase II study of percutaneous radiofrequency ablation for malignant lung tumor (JIVROSG-0702) - Percutaneous radiofrequency ablation for malignant lung tumor (JIVROSG-0702)

Japan Interventional Radiology in Oncology Study Group (JIVROSG)0 个研究点目标入组 33 人开始时间: 2008年11月12日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Exclusion criteria consisted of the following: (i) placement of a cardiac pacemaker; (ii) difficulty placing an electrode without penetrating a pulmonary vessel of >=5 mm in diameter; (iii) contact with the heart, aorta, mediastinum, or bronchus/pulmonary vessel of >= 5 mm in diameter; (iv) severe impairment of the contralateral lung; (v) presence of pulmonary hypertension; (vi) presence of a coagulation abnormality; (vii) difficulty in or inability to discontinue anti-platelet or anti-coagulation medications; (viii) an active infection or >=1.0 mg/dL C-reactive protein; (x) fever>=38 degree; (xi) inability to delay the treatment of a non-target lesion more than 4 weeks after protocol treatment; (xii) previous radiotherapy around the target lesion; (xiii) pregnancy or possible pregnancy; (xiv) ineligibility determined by the responding physician.

发起方

Japan Interventional Radiology in Oncology Study Group (JIVROSG)